Kurma Partners is a Paris and Munich-based venture capital firm founded in 2009, now part of the Eurazeo group. It manages approximately €500M across multiple funds including Kurma Biofund (therapeutics) and Kurma Diagnostics (diagnostics and digital health). The firm is a key European financier of healthcare and biotech innovation, particularly through links with academic research institutes and hospitals in France and Germany.

Kurma has neuro-relevant investments including VICO Therapeutics (gene therapy for spinocerebellar ataxia and Huntington's disease, €54M Series B) and Minoryx Therapeutics (neurological rare disease). The firm's Kurma Diagnostics fund covers digital health and diagnostic innovation relevant to neurodiagnostics. Kurma invests primarily in France, Netherlands, Germany, and broader Europe.